Also found in: Dictionary.
Related to Arimidex: tamoxifen



Pharmacologic class: Nonsteroidal aromatase inhibitor

Therapeutic class: Antineoplastic

Pregnancy risk category D


Reduces serum estradiol levels with no significant effect on adrenocorticoid or aldosterone level; decreases stimulating effect of estrogen on tumor growth


Tablets: 1 mg

Indications and dosages

Postmenopausal women with hormone receptor-unknown or hormone receptor-positive advanced breast cancer or with advanced breast cancer after tamoxifen therapy; adjuvant treatment for hormone receptor-positive breast cancer

Adults: 1 mg P.O. daily


• Hypersensitivity to drug or its components
• Women of childbearing age


Use cautiously in:
• ischemic heart disease
• breastfeeding patients
• children (safety and efficacy not established).


• Verify that patient isn't pregnant before giving drug.

Adverse reactions

CNS: headache, weakness, dizziness, depression, paresthesia, lethargy

CV: chest pain, peripheral edema, vasodilation, hypertension, thromboembolic disease

EENT: pharyngitis

GI: nausea, vomiting, diarrhea, constipation, abdominal pain, anorexia, dry mouth

GU: vaginal bleeding, leukorrhea, vaginal dryness, pelvic pain

Musculoskeletal: decreased bone mineral density, fractures, bone or back pain, muscle weakness

Respiratory: dyspnea, cough

Skin: rash

Other: food distaste, weight gain, swelling, hot flashes, flulike symptoms, tumor flare hypersensitivity reactions (including anaphylaxis, angioedema, urticaria)


Drug-diagnostic tests.Hepatic enzymes, low-density lipoproteins, total cholesterol: increased levels

Patient monitoring

Monitor patient closely for hypersensitivity reactions.
• Check regularly for signs and symptoms of thromboembolic disease, especially dyspnea and chest pain.
• Monitor for circulatory overload (suggested by peripheral edema, cough, and dyspnea).
• Assess for signs and symptoms of depression. Evaluate patient for suicidal ideation.
• Monitor liver function test results.

Patient teaching

Instruct patient to immediately notify prescriber if signs and symptoms of hypersensitivity occur (such as itching or swelling of face, lips, or throat).

Advise patient to immediately report signs and symptoms of thromboembolic disease and circulatory overload.
• Emphasize importance of preventing pregnancy during therapy.
• Tell patient to contact prescriber if she develops signs or symptoms of depression.
• Caution patient to avoid driving and other hazardous activities until she knows how drug affects concentration and alertness.
• Advise patient to minimize GI upset by eating small, frequent servings of food and drinking plenty of fluids.
• Inform patient that she'll undergo regular blood testing during therapy.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the tests mentioned above.


a trademark for an aromatase inhibitor (anastrozole) used for treating estrogen-receptor-positive breast cancer, primarily in postmenopausal women.


An aromatase inhibitor, which converts androstenedione to estradiol in peripheral fat.
Postmenopausal women with advanced oestrogen-dependent breast cancer that does not respond to tamoxifen; unlike tamoxifen, anastrozole is not associated with increased risk of endometrial cancer.


Anastrozole Oncology A nonsteroidal 3rd-generation selective aromatase inhibitor used to manage postmenopausal ♀ whose advanced breast CA is resistant to tamoxifen. See Breast cancer.


A brand name for ANASTROZOLE.
References in periodicals archive ?
Data Source: 10-year follow-up data from the Arimidex, Tamoxifen Alone or in Combination (ATAC) trial.
The ad opens by trumpeting a new product, Arimidex, which, after a five-year study has shown that given to women after surgery, it "has been effective in reducing the risk of breast cancer recurrence for some women.
Research published in the Lancet Oncology found women with early breast cancer who switched to Arimidex after using the standard drug Tamoxifen, for two to three years following surgery reduced chances of dying by 29%.
A trial with Arimidex immediately after surgery showed an extra 26 per cent cut in cancer recurrence on top of the 50 per cent reduction provided by tamoxifen.
They are Arimidex, Femara and Aromasin and will be available on the NHS alongside the "gold standard" drug tamoxifen.
The change comes after Arimidex was granted a new licence following the National Institute for Health and Clinical Excellence's draft approval for funding on the NHS.
The guidance, which relates to femara (letrozole), aromasin (exemestane) and arimidex (anastrozole), is preliminary and subject to consultation.
Arimidex will now replace Tamoxifen after breast surgery - and has fewer side effects.
Three international trials involving 4,000 women showed switching from standard therapy to Arimidex after two years can reduce death rates by 29%.
The drug, Arimidex, dramatically reduces the chances of cancer returning in older women after surgery.
Arimidex was unveiled this week as 10pc more effective at treating the disease.